All In Biotech

Drug Trial Radar · NCT04820452

A Study of IBI302 in Patients With nAMD

A Multi-center, Randomized, Double-blind, Active-controlled Phase II Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Apr 28, 2021

Primary completion

Jan 13, 2023

Study completion Jan 13, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • Low dose IBI302Biological

    Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection

  • High dose IBI302Biological

    High dose IBI302 intravitreal injection given as every other month after three loading monthly injection

  • AfliberceptDrug

    Intraocular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The visual efficacy of IBI302Time frame: Baseline to week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Innovent Biologics (Suzhou) Co,Ltd.

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.